SKTO Secures Additional Acres for the Cultivation of Medical Marijuana
News May 20, 2013
A portion of the newly secured land has been engaged in the legal cultivation of medicinal marijuana for a number of years, specializing in the development of high-CBD strains, and certain strains specifically designed for the new non-psychoactive cannabis-based medicinal marijuana being developed for the pharmaceutical market.
Over the past two months, SK3 Group, Inc has secured an aggregate of over 50 acres of land for medical marijuana cultivation. The land secured by SK3 Group will enable the collectives to maintain a perpetual harvest year round. Part of the fertilizer / nutrient needs for this new facility will be supplied by the byproducts of the Southern California facilities, which incorporate aquaculture with hydroponics. The newer land acquisition in Northern California utilizes several proprietary technologies to produce the finest medicine year round, in a very energy-efficient manner. The facility combines greenhouse growing with HID and LED enhancement, photoperiod control via light deprivation, growth acceleration by C02 enhancement (utilizing captured CO2), and hydroponic growing techniques utilizing organic nutrients and enzyme teas.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.